Euroespes SA
MAD:EEP
Net Margin
Euroespes SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| ES |
|
Euroespes SA
MAD:EEP
|
3.9m EUR |
-35%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
182.6B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
146B USD |
14%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
73.3T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.6B CHF |
10%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
263.4B CNY |
32%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.3B USD |
18%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
31.5B USD |
8%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.6B USD |
21%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
17.2B EUR |
8%
|
Euroespes SA
Glance View
EuroEspes SA engages in the provision of biomedical services. The company is headquartered in Bergondo, La Coruna. The company went IPO on 2012-06-21. The firm operates a medical center, which focuses on the prevention, diagnosis and treatment of central nervous system disorders, such as Alzheimer and Parkinson, and other common diseases. The Company’s medical offer includes personalized treatment plans, genomic medicine, epigenetics, neuropsychology, neuro-ophthalmology, digital diagnosis, diagnostic imaging, clinical analysis and nursing services, among others. In addition, it provides pharmacogenetics services and Human Identification Genetics card, which identifies user's deoxyribonucleic acid (DNA) profile. The firm operates through a number of subsidiaries, such as in Euroespes Biotecnologia SA, Distribuidora de Productos SL and Ebiotec Pharma SL.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Euroespes SA's most recent financial statements, the company has Net Margin of -35.3%.
You don't have any saved screeners yet